These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11772238)

  • 61. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
    Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
    Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
    [No Abstract]   [Full Text] [Related]  

  • 64. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
    Agoulnik IU; Weigel NL
    J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
    Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M
    Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
    Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
    Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype.
    Bergström SH; Rudolfsson SH; Bergh A
    Neoplasia; 2016 Mar; 18(3):152-61. PubMed ID: 26992916
    [TBL] [Abstract][Full Text] [Related]  

  • 68. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
    Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
    Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
    D'Antonio JM; Ma C; Monzon FA; Pflug BR
    Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
    Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
    Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Biology of castration-recurrent prostate cancer.
    Azzouni F; Mohler J
    Urol Clin North Am; 2012 Nov; 39(4):435-52. PubMed ID: 23084522
    [TBL] [Abstract][Full Text] [Related]  

  • 72. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
    J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
    Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
    Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Management of androgen-independent prostate cancer.
    Diaz M; Patterson SG
    Cancer Control; 2004; 11(6):364-73. PubMed ID: 15625524
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
    Zhang X
    Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer.
    Kyprianou N; Lucien F
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769075
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The anticancer potential of metformin on prostate cancer.
    Zaidi S; Gandhi J; Joshi G; Smith NL; Khan SA
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):351-361. PubMed ID: 30651580
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Targeted therapies for prostate cancer.
    Asatiani E; Gelmann EP
    Expert Opin Ther Targets; 2005 Apr; 9(2):283-98. PubMed ID: 15934916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.